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Abstract
Background: The aim of this case series is to describe the experience of using the non-pneumatic anti-shock
garment (NASG) in the management
of severe Postpartum hemorrhage (PPH) and shock, and the value of implementing this concept in high-complexity
obstetric hospitals.
Methods: Descriptive case series of 77 women that received NASG in the management of PPH with severe
hypovolemic shock from June 2014 to December 2015. Vital signs, shock index (SI), the lactic acid value and
the base deficit were compared before and after NASG application.
Results: Fifty-six (77%) women had an SI > 1.1 at the time shock management was initiated; 96% had uterine atony.
All women received standard does of uterotonics. The average time between the birth and NASG applications was
20 min. Forty-eight percent of women recovered haemodynamic variables in the first hour and 100% within the
first 6 h; 100% had a SI < 1.0 in the first hour. The NASG was not removed until definitive control of bleeding was
achieved, with an average time of use of 24 h. There were no mortalities.
Conclusions: In this case series of women in severe shock, the NASG was an effective management device for the
control of severe hypovolemic shock. It should be considered a first-line option for shock management.
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Resumen
Fondo: El propósito de esta serie de casos es describir la experiencia de utilizar el traje antichoque no neumático
(TANN) en el manejo de la hemorrágia postparto (HPP) y el choque severo, y el valor de implementar este
concepto en hospitales obstétricos de alta complejidad.
Métodos: Series de casos descriptiva de 77 mujeres que requirieron TANN en el manejo de HPP con choque
hipovolémico severo desde junio del 2014 a diciembre del 2015. Se compararon los signos vitales, el índice de
choque (IS), el valor de ácido láctico y el déficit de base antes y después de la colocación del TANN.
Resultados: Cincuenta y seis (77%) mujeres tuvieron un IS > 1,1 en el momento en que se inició el tratamiento del
choque; 96% tenían atonía uterina. Todas las mujeres recibieron una dosis estándar de uterotónicos. El tiempo
promedio entre el nacimiento y la colocación del TANN fue de 20 minutos. Cuarenta y ocho por ciento de las
mujeres recuperaron las variables hemodinámicas en la primera hora y el 100% en las primeras 6 horas; 100%
tenían un IS <1,0 en la primera hora. El TANN no se retiró hasta que se alcanzó el control definitivo de la
hemorragia, con un tiempo promedio de uso de 24 horas. No hubo muertes.
Conclusiones: En esta serie de casos de mujeres en choque severo, el TANN fue un dispositivo de manejo efectivo
para el control de choque hipovolémico grave. Debe considerarse una opción de primera línea para el manejo del
choque.
Palabras clave: Hemorragia postparto, Choque hipovolémico, Tratamiento de emergencia, Trajes gravitatorios
Plain English Summary
Postpartum hemorrhage (PPH) is the principal cause of
maternal death and illness in Latin America. These
women die as a result of heavy, uncontrolled bleeding.
When excessive blood is lost, there is inadequate oxygen
in the main organs; the brain, heart and lungs, and the
woman goes into shock.
The non-pneumatic anti-shock garment (NASG) is a
first line intervention for the management of women
with severe PPH and hypovolemic shock. The NASG
applies circumferential pressure to the lower part of the
body, which increases the blood flow to the brain, heart
and lungs. In this study we report on the experience of
using the NASG in the management of PPH and the
value of implementing the device in obstetric units
where high risk patients are managed.
Seventy-seven patients with postpartum hemorrhage
received the NASG. All women received standard doses
of medications to contract the uterus. At 6 h all women
had recovered their heart rate and blood pressure. Blee-
ding was controlled with the NASG rapidly, and 24 h
later it was removed.
In conclusion, the NASG is a viable management alter-
native in cases of PPH and shock, especially as it is very
easy to use across the different levels of care, from lower
level facilities up to the high-complexity level.
Background
The 2015 inter-agency report on maternal mortality estab-
lished a global maternal mortality ratio (MMR) of 216 per
100 thousand live births. Ninety-nine percent of maternal
deaths were concentrated in developing countries and
hemorrhage was the principal cause of maternal mortality
and morbidity in Latin America [1–4]. In 2015 in
Colombia, where this study was conducted, the MMR was
52 per 100 thousand live births [5], approximately 50% of
deaths were due to hemorrhage; the majority of
hemorrhage was due to postpartum hemorrhage (PPH) [6].
Mortality due to PPH is directly related to the
duration and the amount of bleeding [7]. With a loss of
blood volume of 40%, hypovolemic shock, multiple
organ dysfunction and global hypoxia develop, with se-
vere metabolic damage. Shock becomes irreversible
when hypothermia, coagulopathy, and metabolic acidosis
(triad of death) are present [8].
The non-pneumatic anti-shock garment (NASG) is a
first-line intervention for the management and stabilization
of women with PPH in hypovolemic shock. The suit applies
between 20 and 40 mmHg of circumferential pressure to
the lower part of the body, which increases the venous flow
and the cardiac output allowing a systematic distribution of
flow to vital organs [9]. The direct compression of the de-
scending aorta counteracts the bleeding from the uterine
arteries and the vasculature of the mesenteric bed [10].
Different comparative studies have shown a reduction
of approximately 50% in maternal mortality due to PPH
following the introduction of the NASG at the tertiary
level [11–15]. A systematic review of five of these studies
(n = 2330) showed a significant reduction in mortality,
loss of blood, and a more rapid recovery of shock index
(SI) in women when NASG was used [16]. A random-
ized clinical trial assessing the rapid implementation of
NASG demonstrated a statistically significant reduction
in SI recovery. These results led to the introduction of
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the NASG in the World Health Organization’s (WHO)
2012 management guide for the management of the
PPH [17] and its inclusion within the 2013 policies for
health and education for medical personnel. The Inter-
national Federation of Gynaecology and Obstetrics
(FIGO) has recommended that NASGs be used for
clinical stabilization and transport of all women with
PPH from lower to higher levels of care [18].
The Fundación Valle del Lili (FVL) is a private non-
profit medical centre with emphasis on the maternity care
of women with complications in the High Complexity
Unit (UACO), which corresponds to an obstetric critical
care unit. The objective of this article is to report the out-
comes obtained after the introduction of the NASG in the
management of women with massive PPH, hypovolemic
shock, and hypoperfusion in UACO.
Methods
This case series was conducted between June 2014 and
December 2015, in the UACO. The primary data sources
were the clinical records in the patient’s file. Data were
collected using a tool specifically designed to collect the
variables of interest. Demographic variables were collected,
as were variables related to the hemorrhage etiology,
management, and outcomes for the patient cohort.
We developed the research protocol according to
requirements of the Clinical Investigations Centre at the
FVL. The Institutional Ethics Committee at FVL
approved the protocol. All women and their families
were informed of the need to use NASG, and were also
informed regarding the technical, health, and safety
aspects of the device.
The case series included all the pregnant women who
presented with PPH (loss of more than 500 or 1000 mil-
liliters (mL) after vaginal delivery or Caesarean section,
respectively), with hemodynamic instability (hypovol-
emic shock), and clinical indicators confirming hypoper-
fusion. We used the NASG to control bleeding in
conjunction with the institutional clinical protocol for
the management of PPH. The diagnosis of hypovolemic
shock was classified using Baskett’s criteria [19].
In all women, Shock Index (SI), the ratio between the
heart rate and the systolic blood pressure, was measured
at the time of diagnosis. SI has been studied in the obste-
tric population as a valuable marker of hemodynamic in-
stability in cases of massive PPH, and has been found to
be directly related to the probability of massive transfusion
and the development of coagulopathy [20, 21].
The variables hypoperfusion, lactic acid and base def-
icit (mmol/L) were measured at the time of diagnosis of
PPH and at 24 h after diagnosis [22]. The institutional
clinical protocols in the intensive care, high complexity
units of the FVL requires measurement of the Acute
Physiology and Chronic Health Evaluation II (APACHE II)
score for all women in order to evaluate and classify the
acuity of their critical state. In this series, the score was
established for all women in the first 24 h after the haem-
orrhage. Recovery from hypovolemic shock and hypoper-
fusion is assumed in women with an SI of ≤ 1, with lactic
acid < 2 mmol/L and/or a base deficit < −6 mmol/L. We
excluded women who were admitted to the institution
with an NASG from other institutions, with haemo-
dynamic alterations due to another condition, with haem-
orrhage prior to delivery due to an obstetric aetiology, and
those with previously documented coagulation disorders.
The standard medical protocol for PPH treatment
included uterotonic medications. The first choice was
Oxytocin with doses from 80 to 160 mile-units (mU)
per minute via drip with an infusion pump. Methyler-
gometrine was the second-choice drug in doses of
0.2 milligrams (mg), intramuscularly, at the beginning
of the treatment, followed by a second dose at
20 min and then every 4 h, up to a total of five doses
(Methylergometrine was used only if the patient was
not hypertensive and had no contraindications for its
usage). The third choice was Misoprostol with a dose of
800 micrograms (mcg) sublingually, or intra-rectally, where
sub-lingual delivery was not possible.
The data analysis was carried out using STATA®. The
quantitave comparison between status at time of NASG
application and recovery was performed using non-
parametric methods (median and quartiles) and the
categorical variables were analyzed using a distribution
of frequencies. The APACHE II was divided into two
levels, taking into account the median of the distribution.
Results
A cohort of 77 women was identified, with postpartum
hemorrhage and hypovolemic shock, hypoperfusion, all
of whom received the NASG. This cohort corresponded
to 33.9% of the total of pregnant women with PPH who
were treated at the UACO during the study period. The
workload of the High Complexity Obstetric Care unit
for 2015 was 2104 deliveries. The main characteristics of
the women are described in Table 1.
The main diagnosis at admission was severe pre-
eclampsia (32%), followed by premature rupture of
membranes (5%). The perinatal outcome was live birth
in 88% of cases, with a median birth weight of 3137 g
IQR (2555–3560 g). There were six cases (7%) with
multiple pregnancies and nine stillbirths (three cases
with early-onset severe preeclampsia, two cases with pla-
cental abruptio and 4 without indeterminate etiology).
The principal hemorrhage aetiology was uterine atony
(96%), 15% had retained placental tissue, and 5% had
Placenta Previa. Six percent of women experienced a
grade III vaginal tear at the time of delivery.
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Seven (9%) patients with PPH were transferred from
other hospitals. Among the women who started
hemorrhage in our setting, the median time between the
birth and NASG placement (placed at the time of recog-
nition of hypovolemic shock) was 20 min IQR (10–42
min). Fifty-four women (70%) received an intrauterine
tamponade with a Bakri balloon for 24 h, and eight (10%)
were taken for B-lynch surgery. The NASG remained on
these women. Two women with severe preeclampsia pre-
sented exsanguinating haemorrhage, which required a total
abdominal hysterectomy (TAH) and damage control sur-
gery. The NASG was not removed until definitive control
of bleeding and hemodynamic stabilited was achieved. The
majority of women had the NASGs removed by 24 h. Once
removed, there was no need to reuse it in any patient.
Visual bleeding was estimated to be greater than 1000 mL
in all women at the time the NASG was placed. The sum-
mary of the measurement of hypoperfusion and shock vari-
ables is shown in Table 2. Fifty-six women (73%) presented
with a shock index ≥ 1.1 at the initiation of NASG.
Plotting individual lactate paired values before and
after NASG placement with interval time of 24 h is
showed in Fig. 1
100% of the women recovered normal heart rate and sys-
tolic blood pressure in the first 6 h of NASG use, 48% in
the first hour, 100% of women presented an SI < 1 after the
first hour of usage, shown in Fig. 1.
40.8% of the women received a transfusion of blood
products. The administrations of blood products and
intravenous fluids during the 24 h of NASG usage are
described in Figs. 2 and 3.
Two women who received haemostatic surgery showed a
level of lactic acid of 12mmol/L, a base deficit of −22mmol/L
and an APACHE II score of 15. These two women recovered
their vital signs following 24 h of management (0.8 mmol/L
and −6.4 mmol/L, lactic acid and the base deficit values,
respectively). No patient presented any infectious complica-
tions and nomaternal deaths occurred in this cohort.
Discussion
In this cohort of 77 women with hypovolemic shock and
hypoperfusion secondary to PPH; 100% had an SI > 1.1 at
Table 2 Comparison of Diagnostic variables for shock and hypoperfusion in women with PPH at time of NASG placement and removal
Shock variable Number of Women: 77
When NASG applied When NASG removed
Shock index (%)
● 0.5–0.9
● 1–1.5
● >1.5
0
62 (81%)
15 (19%)
75 (97%)
2 (3%)
0
Lactic acid valueb 3.1 ± 1.8 mmol/L
Minimum and maximum values (0.9–12) mmol/
1.3 ± 0.6 mmol/L Minimum and maximum
values (0,7–4.1) mmol/L
Mean difference in lactic acid 1.8 (±1.8) mmol/L
Base deficita −7.4 ± 3.6 mmol/L Minimum and maximum values (−1.7–22) mmol/L −4.2 ± 1.9 mmol/L Minimum and maximum
values (−0.5/–8.5) mmol/L
Haemoglobin 24 h after PPHb 9.5 ± 1.8 g/dL Minimum and maximum values (5.2–14.1) g/dL
APACHE (1st hour)b 8 (6–11) Minimum and maximum values (2–21)
aMean (SD: Standard Deviation)
bMedian (IQR: Interquartile Range)
Table 1 Patient characteristics
Characteristics Total number of women: 77
Agea 25 ± 6
Minimum and maximun
(14–43)
Gestational stage at admissionb 38 (34–39)
Gestational stage
minimum-maximum
(20–41)
Antenatal care visits 70 (90%)
Number of patients
● 1–2 visits
● 3–5 visits
● >5 visits
10 (14%)
29 (42%)
31 (44%)
Level of education
● None
● Primary
● Secondary
● University
6 (8%)
7 (9%)
36 (47%)
28 (36%)
Parity at time of admission
● Primiparous
● Second pregnancy
● Third pregnancy
● > Three pregnancies
40 (52%)
27 (35%)
6 (8%)
4 (5%)
With no previous complications 58 (75%)
Vaginal delivery 53 (69%)
Induced delivery 10 (13%)
Days hospitalizedb 4 (3–7)
Days hospitalized in the ICUb 3 (2–3)
aMean (SD: Standard Deviation)
bMedian (IQR: Interquartile Range)
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the time NASG application and 100% had SI of < 1.0 in the
first hour after placement of the NASG, with no mortality.
The NASG device was introduced to the UACO in
July 2014 with full approval by the medical staff, after a
comprehensive review of the available evidence [8–18].
Despite a gradual increase in the number of women
presenting with PPH since the introduction of the
NASG, there has been a progressive decrease in the per-
centage of women with TAH and damage control sur-
gery, which may be associated with an improvement in
the management strategies that included the use of
NASG.
This case series of the NASG as part of the management
of women with hypovolemic shock due to PPH, is among
the first in which the magnitude of haemodynamic impair-
ment was objectively corroborated with SI, lactic acid
concentrations and the base deficit measurement at the
time of the placement of the NASG and at 24 h after
placement. The SI is reportedly the most accurate clinical
parameter to determine blood loss by PPH. When the
value is ≥ 1.0, it is directly related with haemodynamic in-
stability in massive PPH; if it is > 1.1, it will (in 89% of all
cases) require massive transfusion [19–21].
The effect of the swift application of NASG on the
resuscitation of women with PPH has been previously
reported, showing that when this process occurs in the
first 2 h after the haemorrhagic event, the risk of death
is reduced by 57% [23]. The average time for NASG
implementation in this cohort was 20 min and, in all
cases, it was applied in less than 1 h. This may be
Fig. 1 Mean Difference in lactate Level between Before/After
NASG placement
Fig. 2 Shock Index Changes during the first 6 h and at 24 h of using the NASG. (BG: Before Garment)
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associated with the rapid clinical recovery in SI, where
100% of the women presented an SI of < 1.0 after the
first hour of NASG use.
The successful NASG use in conjunction with Bakri bal-
loons in a severely ill patient with PPH has been described
on only one occasion [24]. In our cohort, 54 women (70%
of the total), received a Bakri balloon and an NASG as a
“sandwich” approach; all women had a rapid recovery.
These outcomes may be secondary to the combination of
the effects of the NASG restoring the circulatory volume
while decreasing blood flow through the external com-
pression of blood vessels and to the internal pressure of
the Bakri ballon against the inside of the uterus (Bakri
balloon). This combination is a relatively low-cost, non-
surgical, intervention that allows a very close monitoring
of uterine bleeding with good effectiveness [25]. There
was no evidence of any differences in the recovery time,
or of the decrease in SI, in the women who received both
therapies (NASG or NASG + Bakri Balloon).
Our findings were similar to other studies that reported
the successful use of NASG in women who also received
B-lynch surgery, hysterectomy or damage control surgery
[12]. In our cohort, eight women received hemostatic
surgery and two women received a hysterectomy and
damage control surgery. In no case was the NASG
removed during surgery. The timing of removal of the
NASG was based on the traditional indications and
traditional perfusion variables indicating hemodynamic
stability; no replacement was necessary after removal in
any case.
Based on the literature [26], there was a 90% probabi-
lity of the need for massive transfusion for the women in
this series who had an SI ≥ 1.1 (72% (n = 54) of the total
sample). Despite the magnitude of the bleeding, only
40% of the women required a transfusion of blood pro-
ducts and these were administered in the majority of
cases in the first hour of management; 37% (n = 29)
women received a transfusion of red blood cells, of
whom 33% (n = 25) received two units. Only three
women (3.8%) received a massive transfusion with red
blood cells, platelets, plasma and cryoprecipitate. This
result has important implications for low-resourced
settings where blood availability is low.
The use of NASG in severely compromised women,
alongside the management protocol described by the
UACO, led to recovery from hypoperfusion and achieved
the resuscitation goals in all women in the first 24 h; the
majority of women recovered in the first hour after NASG
application. Although this series is not intended to
demonstrate the unique effect of NASG in these results,
its incorporation in the management of these severely ill
women enabled the control of bleeding and the swift
recovery of cellular oxygenation, thus avoiding organ
dysfunction and death.
In the present cohort, no adverse events or major com-
plications were found. The median value for the APACHE
Fig. 3 Administration of blood products and intravenous fluids with the NASG during the 24-h period
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II score in this cohort was 8, with an attributable expected
mortality of 10% in these women; as has been seen, there
was no case of maternal mortality. Future research should
compare baseline or pre-intervention outcomes of the
same variables with NASG implementation.
Conclusions
The success of the NASG, in conjunction with medical
and surgical strategies for the management of women with
PPH and hypoperfusion, suggests that this device should
become part of the protocol for handling hypovolemic
shock secondary to severe hemorrhage in the labour units
of high-complexity hospitals. Its use may decrease the
probability of more invasive treatments, higher rates and
volumes of blood transfusions, and costs. Even in women
who required rescue strategies to control bleeding, the
concomitant use of the NASG was not associated with
any major complications, and could be associated with
better outcomes in women with an 80%, or higher, like-
lihood of dying at the time of the placement of the NASG.
In this study the NASG was an aid to rapid restoration
of circulatory normality, and helped avoid metabolic de-
rangement and service burdens, such as need for massive
transfusion or surgery. The variety of clinical experiences
reported with the use of NASG suggests its effectiveness
accross a wide range of settings and resources. Based on
the present report, we believe that the NASG is a viable
tool for managing women with hypovolemic shock sec-
ondary to severe PPH at the highest referral level. It is easy
to learn how to apply, there are no safety issues, and it can
be used across different levels of care, from the smallest
primary health care unit up to the high-complexity level.
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